

CASE REPORT

Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?

Barbara Castelnuovo¹, Agnes Nanyonjo¹, Moses Kanya², and Ponsiano Ocama².

1. Infectious Diseases Institute, Kampala, Uganda, 2. Makerere University, Kampala, Uganda.

Introduction: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative.

Case report: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.

Discussion: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse. Therefore we recommend close follow up for patients that are switched from stavudine to zidovudine and, in case lactate measurement is not possible, free programs should provide safer drugs such as abacavir and tenofovir for patients that develop hyperlactatemia.

African Health Sciences 2008; 8(2): 133-134

Introduction: The prognosis of Ugandan patients with HIV infection has improved with increased access to free antiretroviral therapy (ART). The first-line combination therapy recommended by the National Guidelines includes zidovudine or stavudine plus lamivudine, in combination with either nevirapine or efavirenz¹. Stavudine^{2,4} and to a much lesser extent zidovudine⁵ use is associated with type B lactic acidosis (without hypoxemia). Because most of patients are started on stavudine containing regimens, this rare, but potentially fatal syndrome has become of great concern in resource limited settings (RLS)^{6,7}. Both diagnosis and management of this condition are difficult, leading to high mortality among patients (7- 21%)^{6,7}. The treatment of lactic acidosis/symptomatic hyperlactatemia is supportive (intravenous fluids, mechanical ventilation, and dialysis) and presumed causative drugs should be discontinued and substituted with a nucleoside reverse transcriptase inhibitors (NRTI) less likely to cause this syndrome such as tenofovir and abacavir. However these agents are expensive and often not available in RLS. Therefore patients who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies^{8,9} that demonstrate that this agent can be a safe alternative. Recently however, we observed a case of relapse of symptomatic hyperlactatemia in a patient that was switched from stavudine to zidovudine.

Case history

A 60 year old female was started on free fixed dose combination of stavudine (30 mg) plus lamivudine plus nevirapine at the Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda.

Corresponding author

Barbara Castelnuovo
Infectious Diseases Institute
Mulago Hospital, Kampala, Uganda
PO box 22418
+256 755 360626
bcastelnuovo@idi.co.ug

The clinical, immuno-virological and treatment history is summarized in table 1. The baseline weight, CD4+ count and viral load were 38 kg, 27 cells/mL, and 202,000 copies/ml respectively. By month 6 on ART she developed features of lipodystrophy and complained of mild peripheral neuropathy.

Nineteen months after starting on ART she started complaining of severe abdominal pain associated with vomiting.

The clinician that assessed the patient suspected symptomatic hyperlactatemia and referred her for laboratory testing. Serum lactate was found to be 5.2 mmol/L (normal range 0.5-2.2 mmol/L) and the elevation was attributed to stavudine use.

The patient was switched from stavudine to zidovudine without waiting for lactate levels to revert to normal. The lactate levels were constantly monitored and 5 months after the switch they had normalized (1.6 mmol/L). Ten months after the switch to zidovudine the patient presented with anorexia, vomiting, and 4 kg weight loss. A number of laboratory testing were done and these showed a CD4+ count of 129 cell/mL, viral load of < 400 copies/ml and serum lactate of 3.7 mmol/L; other common causes of hyperlactatemia such as malaria, sepsis, diabetes, liver/renal failure, excessive exercise, dehydration, were excluded. An ultrasound was performed and didn't show any liver abnormalities. Antiretroviral therapy was discontinued and she could not be switched to another combination for lack of tenofovir or abacavir in the free treatment program she was enrolled in. Two months after the interruption the patient deteriorated clinically, experienced weight loss, night fevers and persistent cough. Ziel-Nielsen (ZN) stain on sputum was positive and she was started on anti-tuberculosis drugs. At her last clinic visit her CD4+ count and viral load were 24 cell/mL and 391,898 copies/ml respectively; the patients was started on tenofovir plus emtricitabine plus efavirenz since the Infectious Diseases Institute has agreed to pay for tenofovir after this case was presented in a weekly meeting where clinicians discuss and agree on the management of difficult and complicated cases.

Table 1. Summary of clinical, immuno- virological history

Visit number	Weightkg	Other symptoms of mitochondrial toxicity		CD4+ countcell/ μ L		
Viralload copies/ml		Serum lactatemml/L	NRTI backbone			
ART start	34	none	27	203,000		d4T + 3TC
6 months	37	PN, lipoathropy	103	<400		d4T + 3TC
12 months	37	PN, lipoathropy	121	<400		d4T + 3TC
18 months	38	PN, lipoathropy	127	<400		d4T + 3TC
19 months	40	PN, lipoathropy	nd	nd	5.1	AZT+3TC
24 months	38	lipoathropy	128	<400	1.6	AZT+3TC
30 months	32	lipoathropy	119	<400		AZT+3TC
31 months	34	Abdominal pain, vomiting	nd	nd	3.7	ART Stopped
33 months*	31	none	nd	nd	2.5	OffART
36 months	30	none	24	391,898	1.7	TFV +FTC

* Patient developed pulmonary tuberculosis, sputum positive.

NRTI: nucleoside reverse transcriptase inhibitor; ART: antiretroviral therapy; d4T: stavudine; 3TC: lamivudine; PN: peripheral neuropathy; nd: not done; TFV: tenofovir; FTC: emtricitabine; nd: not done

Discussion

Lactic acidosis is classified into two categories: in type A lactic acidosis occurs in the setting of poor tissue perfusion or oxygenation while in type B lactic acidosis there is no clinical evidence of poor tissue perfusion and the high lactate levels are due to delayed clearance, accelerated aerobic glycolysis or biochemical alterations (dysfunction of the pyruvate dehydrogenase or oxidative phosphorylation).

NRTI antiretroviral drugs can cause an increase in lactate levels interfering with the oxidative phosphorylation through the inhibition of the DNA polymerase γ and therefore depletion of mitochondrial DNA.

Hyperlactatemia associated with zidovudine use is exceptional but has already been described in developed countries⁵. In those settings patients that develop lactic acidosis/symptomatic hyperlactatemia are switched to safe drugs such as tenofovir or abacavir. Bolhaar et al⁷ concluded in their article that the substitution of stavudine with zidovudine could be safe. However the period of observation was relatively short; moreover this substitution could pose challenges in RLS where serum lactate testing is seldom available.

This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse.

In the context of free antiretroviral treatment programs, the majority of patients are started on stavudine containing regimens but alternative drugs, such as abacavir and tenofovir are often not provided as well as lactate measurement facilities.

Therefore we recommend close follow up for patients that are switched from stavudine to zidovudine and, in case lactate measurement is not possible, free programs should provide safer drugs such as abacavir and tenofovir for patients that develop hyperlactatemia.

References

1. National antiretroviral treatment and care guidelines for adults and children. 1st edition. Kampala, Uganda: Ministry of Health, Republic of Uganda, 2003.
2. Carr A, Miller J, Law M, and Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related syndrome. *AIDS* 2000; 18:F25–32.
3. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 2001; 33:1931–7.
4. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, and Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. *AIDS* 2002; 16:1341–9.
5. Sundar K, Suarez M, Banogon PE, and Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. *Crit Care Med* 1997; 25:1425–30.
6. Mwebaze S, Castelnuovo B, Birabwa E, Ocamo P, and Kambu A. Symptomatic hyperlactatemia associated with Nucleoside analogue reverse-transcriptase inhibitor use in HIV infected patients: a report of 24 cases in a resource limited setting (Uganda). *CID* 2007; 45:514-17.
7. Bolhaar M, and Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. *CID* 2007; 45:254-60
8. Lonergan JT, Barber RE, and Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. *AIDS* 2003; 17:2495–9.
9. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. *J Acquir Immune Defic Syndr* 2004; 36:935–42.